Q-omics provides the consensus-scored C9orf131 profile across patient tissues and cancer cell-line models. C9orf131 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, C9orf131 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, C9orf131 RNA expression shows 15,846 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, HNSC, and THYM as cancer lineages where C9orf131 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C9orf131 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C9orf131 survival associations across molecular data types. C9orf131 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C9orf131 RNA expression–survival associations across cancer types. High C9orf131 expression shows unfavorable associations in LUSC, but favorable associations in BRCA, HNSC, KIRP, COAD and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for C9orf131 RNA expression.
This table summarizes C9orf131 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for C9orf131. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C9orf131 shows lower tumor expression in THCA, BRCA, LUAD and LUSC and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher C9orf131 RNA expression in tumor versus normal tissue (log2 FC = +0.079, t-test p = .008).
This table shows molecular features associated with C9orf131 in patient tissues and cancer cell lines. In patient samples, C9orf131 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C9orf131 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
